This may be a temporary setback, but long-acting antiretroviral therapy is still on the way, experts say.
The likely launch of injectable cabotegravir/rilpivirine in early 2020 will be interesting, writes David Wohl, M.D. One big question: How smoothly will the rollout go?
This is clearly an antiretroviral not built for daily administration. But then what is it destined for?
Taking more than five medications could be a problem. And many people with HIV are at risk of being on medication overload.
The new public-private partnership will put $200 million toward finding eventual cures for two of the world's most pervasive diseases.
New analysis of the LATTE trial shows the two drugs cabotegravir and rilpivirine may also work as a daily oral formulation, which could be a bridge therapy for people who miss an injectable appointment.
Researchers reported hopeful news on regimens with lower treatment burdens and newly developed antiretrovirals.
Six thousand HIV researchers and experts are expected to make their way to Mexico City for the 10th International AIDS Society Conference on HIV Science, which will feature more than 1,000 abstracts highlighting the latest findings in HIV treatment, prevention, and public health policy.
People with college education, gay and bisexual men, and people who struggle to make clinic visits were more likely to prefer the long-acting option.